FULCRUM THERAPEUTICS, INC. Stock Issued During Period, Value, Employee Benefit Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for the quarter ending 2026-06-30 was $355.00K, a 17.94% increase year-over-year.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for the quarter ending 2026-03-31 was $21.00K.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for the quarter ending 2025-09-30 was $64.00K, a 89.92% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for the quarter ending 2025-06-30 was $301.00K, a 20.16% decline year-over-year.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for fiscal 2023 was $777.00K, a 77.92% decline from fiscal 2022.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for fiscal 2022 was $3.52M, a 4.06% decline from fiscal 2021.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for fiscal 2021 was $3.67M, a 156.50% increase from fiscal 2020.
- FULCRUM THERAPEUTICS, INC. stock issued during period, value, employee benefit plan for fiscal 2020 was $1.43M, a 465.22% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, Employee Benefit Plan 3 month | Stock Issued During Period, Value, Employee Benefit Plan 12 month |
|---|---|---|
| 2026-06-30 | $355.00K S-4 · filed 2026-09-02 | |
| 2026-03-31 | $21.00K S-4 · filed 2026-09-02 | |
| 2025-12-31 | $4.17M S-4 · filed 2026-09-02 | |
| 2025-09-30 | $64.00K 10-Q · filed 2025-10-29 | |
| 2025-06-30 | $301.00K S-4 · filed 2026-09-02 | |
| 2024-12-31 | $2.75M S-4 · filed 2026-09-02 | |
| 2024-09-30 | $635.00K 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $377.00K 10-Q · filed 2025-10-29 | |
| 2024-03-31 | $1.65M 10-Q · filed 2025-10-29 | |
| 2023-12-31 | $777.00K 10-K · filed 2025-02-25 | |
| 2023-06-30 | $141.00K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $348.00K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $3.52M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $93.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $2.76M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $395.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $3.67M 10-K/A · filed 2023-06-26 | |
| 2021-09-30 | $2.40M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $242.00K 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $93.00K 10-Q · filed 2022-11-08 | |
| 2020-12-31 | $1.43M 10-K/A · filed 2023-06-26 | |
| 2020-09-30 | $87.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $525.00K 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $286.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $253.00K 10-K/A · filed 2023-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |